American HealthCare Capital is pleased to introduce a Pharmaceutical Intellectual Property and Development company. The initial work of the company has centered on OTC topical active pharmaceutical ingredients (API) and existing OTC Monographs. The company has developed a dual-action carrier formulation that is utilized in creating groundbreaking efficacy and improvement of existing topical applications.

Their formulations have global implications and opportunities to improve disease and healthcare outcomes by addressing multi-drug resistant bacteria and fungal infections. These “superbugs” are listed as global healthcare threats, and the formulations are the only topical products to deal with these growing threats (examples are MRSA, Acinetobacter, Pseudomonas, E.coli and Candida auris).

The current IP catalog was acquired in 2016, and multiple investors were brought in since then. The pharma intellectual property and development company has spent this time solidifying the data and proof of concepts around their formulations within different verticals of healthcare and consumer health. Data is available to support all statements around each product category.

The company’s goal is to out-license individual formulations or Intellectual Property to a company that can expand these products into the marketplace. They are also open to identifying an acquisition company for the platform within the pharmaceutical or consumer healthcare areas. They are willing to discuss all reasonable prices and structures regarding this pharma M&A.

If you would like to learn more, please use the link on the right-hand side of the page to execute our NDA. You will need to copy the Listing Code (Example: TXMC1A) and Listing Title (Example: $1 Million Home Health Agency in Texas) from the summary above to complete the NDA.